PMID- 34763450
OWN - NLM
STAT- MEDLINE
DCOM- 20231013
LR  - 20231013
IS  - 2224-5839 (Electronic)
IS  - 2224-5820 (Linking)
VI  - 10
IP  - 10
DP  - 2021 Oct
TI  - Sodium-glucose cotransporter-2 inhibitors protect against atrial fibrillation in 
      patients with heart failure.
PG  - 10887-10895
LID - 10.21037/apm-21-2694 [doi]
AB  - BACKGROUND: Heart failure (HF) often complicates atrial fibrillation (AF) and 
      conversely, AF frequently complicates HF. Furthermore, the coexistence of both 
      conditions significantly increases the risk of cardiovascular complications. 
      Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have been demonstrated to 
      decrease hospitalizations for HF and reduce cardiovascular death. Therefore, this 
      study evaluated the effects of SGLT-2 inhibitors on AF in patients with HF. 
      METHODS: A total of 903 patients with HF were enrolled in this study. Basic 
      patient data including demographic characteristics, medical history, 
      cardiovascular medications, and results of biochemical tests were collated. 
      Logistic regression analysis was performed to examine the association between 
      SGLT-2 inhibitors and the risk of AF. The effects of SGLT-2 inhibitors on AF were 
      further analyzed according to subgroups. RESULTS: Patients treated with SGLT-2 
      inhibitors experienced a lower prevalence of AF (8.4% vs. 12.1%, P<0.001) 
      compared to patients without SGLT-2 treatment. Controlling for potential 
      confounders revealed that SGLT-2 inhibitors decreased the risk of AF by 24% [odds 
      ratio (OR): 0.76; 95% confidence interval (CI): 0.70-0.85; P<0.001]. The effect 
      of SGLT-2 inhibitors on AF was consistent in patients aged < 65 years and 
      patients aged >/=65 years (OR =0.82 and 95% CI: 0.71-0.88 vs. OR =0.84 and 95% CI: 
      0.77-0.92, respectively; P interaction =0.501). Similarly, neither gender, body 
      mass index (BMI), estimated glomerular filtration rate (eGFR), nor the New York 
      Heart Association (NYHA) classification affected the protective effect of SGLT-2 
      inhibitors. CONCLUSIONS: SGLT-2 inhibitors reduced the risk of AF in patients 
      with HF, and the effect was consistent irrespective of age, gender, BMI, eGFR, 
      and NYHA classification.
FAU - Zhou, Lili
AU  - Zhou L
AD  - Department of Electrocardiography and Cardiac Function, The First Affiliated 
      Hospital of Anhui Medical University, Hefei, China; Department of Cardiology, 
      Anhui Maternal and Child Health Hospital, Hefei, China.
FAU - Yang, Yuanyuan
AU  - Yang Y
AD  - Department of Cardiology, Anhui Maternal and Child Health Hospital, Hefei, China.
FAU - Han, Weixing
AU  - Han W
AD  - Department of Electrocardiography and Cardiac Function, The First Affiliated 
      Hospital of Anhui Medical University, Hefei, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Palliat Med
JT  - Annals of palliative medicine
JID - 101585484
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Humans
MH  - *Atrial Fibrillation/drug therapy
MH  - *Heart Failure/drug therapy/prevention & control
MH  - Risk Factors
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
OTO - NOTNLM
OT  - Sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitors)
OT  - atrial fibrillation (AF)
OT  - heart failure (HF)
EDAT- 2021/11/13 06:00
MHDA- 2021/11/16 06:00
CRDT- 2021/11/12 05:27
PHST- 2021/08/17 00:00 [received]
PHST- 2021/10/22 00:00 [accepted]
PHST- 2021/11/12 05:27 [entrez]
PHST- 2021/11/13 06:00 [pubmed]
PHST- 2021/11/16 06:00 [medline]
AID - 10.21037/apm-21-2694 [doi]
PST - ppublish
SO  - Ann Palliat Med. 2021 Oct;10(10):10887-10895. doi: 10.21037/apm-21-2694.